Session

IBD (Posters)

LARGE DIFFERENCES IN IBD CARE AND EDUCATION ACROSS EUROPE, FIRST RESULTS OF THE PAN-EUROPEAN VIPER SURVEY
LARGE DIFFERENCES IN IBD CARE AND EDUCATION ACROSS EUROPE, FIRST RESULTS OF THE PAN-EUROPEAN VIPER SURVEY

IBD (Posters)  et al.

PROLONGED REMISSION OF ULCERATIVE COLITIS USING FAECAL MICROBIOTA TRANSPLANTATION - A CASE SERIES
PROLONGED REMISSION OF ULCERATIVE COLITIS USING FAECAL MICROBIOTA TRANSPLANTATION - A CASE SERIES

IBD (Posters)  et al.

AI AUTOMATED WORKFLOW FOR IMPROVING DETECTION AND SCORING OF ULCERATIVE COLITIS DISEASE ACTIVITY UNDER MULTIPLE SCORING SYSTEMS
AI AUTOMATED WORKFLOW FOR IMPROVING DETECTION AND SCORING OF ULCERATIVE COLITIS DISEASE ACTIVITY UNDER MULTIPLE SCORING SYSTEMS

IBD (Posters)  et al.

A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EFFICACY AND SAFETY OF INFLIXIMAB AND VEDOLIZUMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EFFICACY AND SAFETY OF INFLIXIMAB AND VEDOLIZUMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

IBD (Posters)  et al.

THERAPEUTIC POTENTIAL OF TNK1 IN PREVENTION AND HEALING OF INTESTINAL BARRIER BREACH
THERAPEUTIC POTENTIAL OF TNK1 IN PREVENTION AND HEALING OF INTESTINAL BARRIER BREACH

IBD (Posters)  et al.

IMPAIRED LUMINAL CONTROL OF INTESTINAL MACROPHAGE MATURATION IN PATIENTS WITH ULCERATIVE COLITIS DURING REMISSION
IMPAIRED LUMINAL CONTROL OF INTESTINAL MACROPHAGE MATURATION IN PATIENTS WITH ULCERATIVE COLITIS DURING REMISSION

IBD (Posters)  et al.

SAFETY OF INFLAMMATORY BOWEL DISEASE DRUGS DURING PREGNANCY AND BREASTFEEDING: MOTHERS AND BABIES’ OUTCOMES (DUMBO REGISTRY)
SAFETY OF INFLAMMATORY BOWEL DISEASE DRUGS DURING PREGNANCY AND BREASTFEEDING: MOTHERS AND BABIES’ OUTCOMES (DUMBO REGISTRY)

IBD (Posters)  et al.

COMPARATIVE EFFICACY AND SAFETY OF ORAL FERRIC MALTOL IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH MILD-TO-MODERATE VS. MORE SEVERE IRON DEFICIENCY ANAEMIA
COMPARATIVE EFFICACY AND SAFETY OF ORAL FERRIC MALTOL IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH MILD-TO-MODERATE VS. MORE SEVERE IRON DEFICIENCY ANAEMIA

IBD (Posters)  et al.

THE VARIATIONS OF GUT MICROBIOME FROM ULCERATIVE COLITIS PATIENTS ARE NOT AS GREAT AS EXPECTED
THE VARIATIONS OF GUT MICROBIOME FROM ULCERATIVE COLITIS PATIENTS ARE NOT AS GREAT AS EXPECTED

IBD (Posters)  et al.

IRON DEFICIENCY ANAEMIA IN INFLAMMATORY BOWEL DISEASE: DIAGNOSIS, QUALITY OF LIFE AND IRON TREATMENT PREFERENCES AMONG EUROPEAN PATIENTS
IRON DEFICIENCY ANAEMIA IN INFLAMMATORY BOWEL DISEASE: DIAGNOSIS, QUALITY OF LIFE AND IRON TREATMENT PREFERENCES AMONG EUROPEAN PATIENTS

IBD (Posters)  et al.

EFFECTS OF USTEKINUMAB INDUCTION AND MAINTENANCE THERAPY ON DISEASE CLEARANCE IN THE UNIFI PHASE 3 STUDY IN ULCERATIVE COLITIS
EFFECTS OF USTEKINUMAB INDUCTION AND MAINTENANCE THERAPY ON DISEASE CLEARANCE IN THE UNIFI PHASE 3 STUDY IN ULCERATIVE COLITIS

IBD (Posters)  et al.

THE ASSOCIATION BETWEEN FAECAL SHORT-CHAIN FATTY ACIDS CONCENTRATION AND THE CLINICAL ACTIVITY OF ULCERATIVE COLITIS AND CROHN’S DISEASE - PRELIMINARY STUDY
THE ASSOCIATION BETWEEN FAECAL SHORT-CHAIN FATTY ACIDS CONCENTRATION AND THE CLINICAL ACTIVITY OF ULCERATIVE COLITIS AND CROHN’S DISEASE - PRELIMINARY STUDY

IBD (Posters)  et al.

VEDOLIZUMAB IN REAL PRACTICE: EXPERIENCE IN A TERTIARY HOSPITAL
VEDOLIZUMAB IN REAL PRACTICE: EXPERIENCE IN A TERTIARY HOSPITAL

IBD (Posters)  et al.

ASSOCIATION BETWEEN SERUM VITAMIN D METABOLITES AND HEMATOLOGICAL MARKERS OF INFLAMMATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
ASSOCIATION BETWEEN SERUM VITAMIN D METABOLITES AND HEMATOLOGICAL MARKERS OF INFLAMMATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

IBD (Posters)  et al.

CORRELATION OF EX VIVO MUCOSAL CYTOKINE PROFILES WITH CLINICAL AND ENDOSCOPIC SCORES IN ULCERATIVE COLITIS
CORRELATION OF EX VIVO MUCOSAL CYTOKINE PROFILES WITH CLINICAL AND ENDOSCOPIC SCORES IN ULCERATIVE COLITIS

IBD (Posters)  et al.

PRESENCE OF THE HLA-DQA1*05 ALLELE AND ITS ASSOCIATION WITH THE SECONDARY LOSS OF RESPONSE TO INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
PRESENCE OF THE HLA-DQA1*05 ALLELE AND ITS ASSOCIATION WITH THE SECONDARY LOSS OF RESPONSE TO INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

IBD (Posters)  et al.

IMPACT OF INFLAMMATORY BOWEL DISEASE IN PEDIATRIC PATIENTS AND THEIR FAMILIES ACCORDING TO DISEASE CONTROL
IMPACT OF INFLAMMATORY BOWEL DISEASE IN PEDIATRIC PATIENTS AND THEIR FAMILIES ACCORDING TO DISEASE CONTROL

IBD (Posters)  et al.

VEDOLIZUMAB MAY BE AN EFFECTIVE OPTION FOR THE TREATMENT OF POSTOPERATIVE RECURRENCE OF CROHN’S DISEASE
VEDOLIZUMAB MAY BE AN EFFECTIVE OPTION FOR THE TREATMENT OF POSTOPERATIVE RECURRENCE OF CROHN’S DISEASE

IBD (Posters)  et al.

SEVERE ACTIVITY OF INFLAMMATORY BOWEL DISEASE IS A RISK FACTOR FOR SEVERE COVID-19: DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD)
SEVERE ACTIVITY OF INFLAMMATORY BOWEL DISEASE IS A RISK FACTOR FOR SEVERE COVID-19: DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD)

IBD (Posters)  et al.

THE IMPACT OF NON-MEDICAL SWITCHING FROM ORIGINATOR TO BIOSIMILAR INFLIXIMAB VS CONTINUING ON ORIGINATOR IN INFLAMMATORY BOWEL DISEASE: RESULTS OF PROJECT NORTH
THE IMPACT OF NON-MEDICAL SWITCHING FROM ORIGINATOR TO BIOSIMILAR INFLIXIMAB VS CONTINUING ON ORIGINATOR IN INFLAMMATORY BOWEL DISEASE: RESULTS OF PROJECT NORTH

IBD (Posters)  et al.

Item 341 - 360 / 568
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
18
19 20 21 22 23 24 25 26 27 28 29